CN112203681B - 疫苗组合物及其用途 - Google Patents

疫苗组合物及其用途 Download PDF

Info

Publication number
CN112203681B
CN112203681B CN201980024131.4A CN201980024131A CN112203681B CN 112203681 B CN112203681 B CN 112203681B CN 201980024131 A CN201980024131 A CN 201980024131A CN 112203681 B CN112203681 B CN 112203681B
Authority
CN
China
Prior art keywords
cancer
antigen
seq
vaccine composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980024131.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112203681A (zh
Inventor
N·埃德
U·维德曼
J·托拜厄斯
C·杰林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Gene Ltd
Original Assignee
Immune Gene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900368A external-priority patent/AU2018900368A0/en
Application filed by Immune Gene Ltd filed Critical Immune Gene Ltd
Publication of CN112203681A publication Critical patent/CN112203681A/zh
Application granted granted Critical
Publication of CN112203681B publication Critical patent/CN112203681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201980024131.4A 2018-02-07 2019-02-07 疫苗组合物及其用途 Active CN112203681B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2018900368 2018-02-07
AU2018900368A AU2018900368A0 (en) 2018-02-07 A vaccine composition and uses thereof
AU2018903518 2018-09-19
AU2018903518A AU2018903518A0 (en) 2018-09-19 A vaccine composition and uses thereof
AU2018903968 2018-10-19
AU2018903968A AU2018903968A0 (en) 2018-10-19 A vaccine composition and uses thereof
PCT/AU2019/050089 WO2019153042A1 (en) 2018-02-07 2019-02-07 A vaccine composition and uses thereof

Publications (2)

Publication Number Publication Date
CN112203681A CN112203681A (zh) 2021-01-08
CN112203681B true CN112203681B (zh) 2024-05-24

Family

ID=67547868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024131.4A Active CN112203681B (zh) 2018-02-07 2019-02-07 疫苗组合物及其用途

Country Status (7)

Country Link
US (1) US12311019B2 (https=)
EP (1) EP3749356A4 (https=)
JP (1) JP2021512966A (https=)
CN (1) CN112203681B (https=)
AU (1) AU2019216873B2 (https=)
CA (1) CA3090552A1 (https=)
WO (1) WO2019153042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4393947A4 (en) * 2021-08-25 2025-07-30 Toagosei Co Ltd ANTI-PD-1 SIGNAL PEPTIDE ANTIBODY AND ITS USE
KR102401860B1 (ko) * 2021-10-21 2022-05-24 을지대학교 산학협력단 신규 항암 백신 조성물 및 그를 이용한 백신화 방법
KR102421307B1 (ko) * 2021-11-19 2022-07-14 을지대학교 산학협력단 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122262A1 (en) * 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition
WO2013164694A1 (en) * 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2016021209A1 (en) * 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
CN105358683A (zh) * 2013-07-12 2016-02-24 Vlp治疗有限责任公司 包含pd-1抗原或pd-1配体抗原的病毒样颗粒
CN105431449A (zh) * 2013-04-05 2016-03-23 香港大学 新的pd1同种型及其用于加强免疫应答的用途
WO2016106159A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
WO2016164980A1 (en) * 2015-04-17 2016-10-20 Biolife Science Qld Limited A vaccine composition and uses thereof
WO2016183469A1 (en) * 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
WO2017040790A1 (en) * 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2018183488A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056591A1 (es) * 2005-10-28 2007-10-10 Vaxinnate Corp Polipeptidos ligandos para receptor 4 simil toll (tlr4)
US20120082687A1 (en) * 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122262A1 (en) * 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition
WO2013164694A1 (en) * 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
CN105431449A (zh) * 2013-04-05 2016-03-23 香港大学 新的pd1同种型及其用于加强免疫应答的用途
CN105358683A (zh) * 2013-07-12 2016-02-24 Vlp治疗有限责任公司 包含pd-1抗原或pd-1配体抗原的病毒样颗粒
WO2016021209A1 (en) * 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
WO2016106159A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
WO2016164980A1 (en) * 2015-04-17 2016-10-20 Biolife Science Qld Limited A vaccine composition and uses thereof
WO2016183469A1 (en) * 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
WO2017040790A1 (en) * 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2018183488A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction;Lenka Potocnakova等;J Immunol Res.;第2016卷;全文 *
一种靶向MUC1及PD-1的双靶点蛋白疫苗设计及其体液免疫学分析;邱凌翀等;基因组学与应用生物学;20160325;第35卷(第3期);第513-519页 *

Also Published As

Publication number Publication date
JP2021512966A (ja) 2021-05-20
EP3749356A4 (en) 2021-11-24
US12311019B2 (en) 2025-05-27
WO2019153042A1 (en) 2019-08-15
CA3090552A1 (en) 2019-08-15
AU2019216873A1 (en) 2020-08-20
EP3749356A1 (en) 2020-12-16
AU2019216873B2 (en) 2025-08-14
US20210236614A1 (en) 2021-08-05
CN112203681A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
US10166276B2 (en) Compositions and methods for treatment of non-hodgkins lymphoma
Ladjemi et al. Anti-HER2 vaccines: new prospects for breast cancer therapy
PT2155243E (pt) Composição e métodos compreendendo os antigénios klk3, psca ou folh1
MXPA01003503A (es) Nuevos metodos terapeuticos de vacunacion.
AU2006261342B2 (en) Her-2 peptides
CN112203681B (zh) 疫苗组合物及其用途
CA2763486A1 (en) Casb7439 constructs
JP2009544291A (ja) ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
AU2016250289B2 (en) A vaccine composition and uses thereof
Pietersz* et al. Generation of cellular immune responses to antigenic tumor peptides
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
US20210346484A1 (en) Method of producing a vaccine composition and uses thereof
JP2018520152A (ja) 免疫原性プレプロカルシトニンペプチド
HK1248536B (en) A vaccine composition and uses thereof
CN113318225A (zh) 肿瘤免疫增强剂及其制法和应用
HK1203817B (zh) 自体癌细胞疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant